News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Biotech IPO Scorecard: Who’s Up, Who’s Down in 2013


6/3/2013 8:38:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Remember Plexxikon? The Berkeley, CA-based company had a lot of talent for structural biology-based drug design, an impressive new treatment for melanoma, and a strong management team. Two years ago, nobody on Wall Street cared one whit. Plexxikon flirted with the idea of going public, found little interest, and sold itself off to Japan-based Daiichi Sankyo for a more than 10-fold return on investment. It was a poster child for how dead the biotech IPO market was in 2010 and 2011.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Xconomy


comments powered by Disqus
Xconomy
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES